Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 1218-1222, 2009. First published March 26, 2009; 10.1373/clinchem.2008.113779
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2008.113779v1
55/6/1218    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Scherer, M.
Right arrow Articles by Liebisch, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scherer, M.
Right arrow Articles by Liebisch, G.
(Clinical Chemistry. 2009;55:1218-1222.)
© 2009 American Association for Clinical Chemistry, Inc.

Brief Communications

High-Throughput Analysis of Sphingosine 1-Phosphate, Sphinganine 1-Phosphate, and Lysophosphatidic Acid in Plasma Samples by Liquid Chromatography–Tandem Mass Spectrometry

Max Scherer1, Gerd Schmitz1 and Gerhard Liebisch1,a

1 Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany;

aaddress correspondence to this author at: Institut für Klinische Chemie und Laboratoriumsmedizin, Universität Regensburg, D-93042 Regensburg, Germany. Fax +49-941-944-6202; e-mail gerhard.liebisch{at}klinik.uni-regensburg.de.


Abstract

Background: Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are ubiquitous lipid messengers found in the blood and most cell types. Both lysophospholipids are ligands of G protein–coupled receptors and mediate important physiological processes. Moreover, lysophospholipids are potential biomarkers for various diseases, including atherosclerosis and cancer. Because existing methodologies are of limited value for systematic evaluations of S1P and LPA in clinical studies, we developed a fast and simple quantification method that uses liquid chromatography–tandem mass spectrometry (LC-MS/MS).

Methods: Sphingoid base 1-phosphates and LPA species were quantified in negative-ion mode with fragments of m/z 79 and 153, respectively. The internal standards LPA 17:0 and [13C2D2]S1P were added before butanol extraction. Application of hydrophilic-interaction chromatography allowed coelution of analytes and internal standards with a short analysis time of 2.5 min.

Results: Comparison of butanol extraction with a frequently used extraction method based on strong acidification of human plasma revealed artificial formation of LPA from lysophosphatidylcholine with the latter method. Validation according to US Food and Drug Administration guidelines showed an overall imprecision (CV) of <12% and a limit of detection <6 nmol/L for all lysophospholipid species. Concentrations of S1P and sphinganine 1-phosphate (SA1P) in EDTA-containing plasma were stable for 24 h at room temperature, whereas LPA concentrations increased substantially over this period.

Conclusions: Our validated LC-MS/MS methodology for quantifying LPA, S1P, and SA1P features simple sample preparation and short analysis times, therefore providing a valuable tool for diagnostic evaluation of these lysophospholipids as biomarkers.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Lipid Res.Home page
N. O'Brien, S. T. Jones, D. G. Williams, H. B. Cunningham, K. Moreno, B. Visentin, A. Gentile, J. Vekich, W. Shestowsky, M. Hiraiwa, et al.
Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies
J. Lipid Res., November 1, 2009; 50(11): 2245 - 2257.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.